The Korean Ministry of Justice plans to introduce a bill this year in the National Assembly requiring the collection of DNA from convicted felons. The bill would also require that DNA samples from suspects accused of crimes in 11 categories, including murder and robbery, be collected. Source: The Korea Times
The European Investment Bank (EIB) has agreed to loans totaling €885 million ($1.2 billion) for Turkey. The Turkish government will receive €335 million for 2009–2010 to help finance R&D at the nation’s 15 leading public universities. The funding will also be used to purchase scientific instruments for the universities. Small- and medium-sized enterprises in the […]
Science and technology (S&T) funding in Japan’s fiscal 2009 economic stimulus package totaled ¥1,346.5 billion ($13.5 billion), approximately 10% of the stimulus package. The Ministry of Education, Culture, Sports, Science and Technology (MEXT) received 49% of the funding. Of this amount, ¥300 billion will be allocated to a special fund run by the Japan Society […]
An online survey of 800 chemical industry executives conducted by ICIS and Genomatica in May indicates that sustainable chemistry is gaining momentum. Fifty-seven percent of respondents stated that their companies are already conforming with green chemistry practices, and 47% of respondents said their companies are using renewable feedstocks in manufacturing. Green chemistry is a priority […]
The semiconductor equipment market should begin to improve later this year, having reached bottom in the second quarter. Capital spending by the semiconductor industry is estimated to decline 44.8% this year to $24.3 billion, before rebounding in 2010 to grow 20.9% to $29.4 billion. Capital equipment spending is expected to fall 45.8% this year to […]
Generic drug firms are facing a tougher business environment. In efforts to cut spending, some European countries, have recently reduced the prices they pay for generics. As a result, generic makers are less likely to bid for the contracts, which has allowed the makers of branded drugs to secure the contracts and make a profit […]
Biologics will account for seven of the top 10 selling drugs in five years and half of the top 100 selling drugs, according to EvaluatePharma. Last year, five of the 10 top selling drugs were biologics and 28% of the top 100 were biologics. Of the biologics in the top 5 in 2014, five are […]
Employment at instrument and lab product firms can be expected to decline this year. Numerous companies announced layoffs and hiring freezes in the fourth quarter of 2008 (see IBO 2/28/09) in response to a sharp and sudden downturn in sales, including Varian (see IBO 1/31/09) and Mettler-Toledo (see IBO 3/15/09). In 2009, so far, the […]
June began with renewed economic optimism as data for May came in slightly better than expected. The markets were even reassured following the bankruptcy filing of GM on June 1. Although some market euphoria can be attributed to positive financial media spin, many observers believe the macroeconomic environment is improving and that the US will […]
San Diego, CA 6/22/09; Washington, DC 6/25/09—The US District Court for the Southern District of California has dismissed Beckman Coulter and Orchid Cellmark’s patent infringement suit against Sequenom (see IBO 6/15/08), following the parties’ stipulation for dismissal. Sequenom stated that the patent infringement action was dismissed with prejudice, meaning it cannot be brought again, and […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
